United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917), colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. hypersensitivity to this product or to probenecid or colchicine. probenecid and colchicine tablets are contraindicated in children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid and colchicine should not be started until an acute gouty attack has subsided. pregnancy: probenecid crosses the placental barrier and appears in cord blood. colchicine can arrest cell division in animals and plants. in certain species of animals under certain conditions, colchicine has produced teratogenic effects. the possibility of such effects in humans also has been reported. because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. the use of any drug in women of childbearing potential requires that the anticipated benefit be weighed against the possible hazards.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - for treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - for treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sykes vet (international) pty. ltd. - citric acid; potassium citrate; sodium citrate - oral solution/suspension - citric acid acid-general active 40000.0 mg/l; potassium citrate mineral-potassium active 80000.0 mg/l; sodium citrate mineral-sodium-salt active 280000.0 mg/l - genitourinary system - dog - greyhound | horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | - acidosis | body acid neutraliser | dehydration | diuretic, acidifier or alkaliniser | acidification | acidifier | acidifying | acidosis | alkaliniser | bronchodilator | cardiac stimulant | dehydration | diuresis | diuretic | feline struvite urolithias | fluid retention | hepatotoxic drugs | kidney antiseptic | liver damage | methionine treatment | oedema | parturient udder oedema | retention of fluid | saluresis | stimulant - cardiac | struvite urolithiasis | tonus-improving | tying-up | udder oedema | urinary alkalizer | urinary antiseptic | urinary buffer | urinary calculi | urine | urolithiasis | uterine pessaries

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg - valproic acid capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unle

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is essential to the m

United States - English - NLM (National Library of Medicine)

lannett company, inc. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who

United States - English - NLM (National Library of Medicine)

caraco pharmaceutical laboratories, ltd. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1) for statement regarding fatal hepatic dysfunction. valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see warnings and precautions (5.1)] . valproic acid is contraindicated in patients with known hypersensitivity to the drug [see warnings and precautions (5.

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - levomefolic acid (unii: 8s95dh25xc) (levomefolic acid - unii:8s95dh25xc), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium carbonate ( - levomefolic acid 600 ug - this product is contraindicated in patients with a known hypersensitivity to any of the ingredients, including soy or fish products.

Israel - English - Ministry of Health

sanofi israel ltd - valproic acid; valproic acid as sodium - tablets prolonged release - valproic acid 145 mg; valproic acid as sodium 333 mg - valproic acid - epilepsy:treatment of generalized or partial epilepsy secondary epilepsy and mixed forms of epilepsy. bipolar disorders: treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. the continuation of treatment after manic episode could be considered in patients who have responded to valproic acid for acute mania.